Genome Editing of Pik3cd Impedes Abnormal Retinal Angiogenesis
Human Gene Therapy · 2023
DOI: 10.1089/hum.2022.079 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Gene Therapy, 2023. Verfasst von Wenyi Wu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Hunan Key Laboratory of Ophthalmology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Cent…. Hauptthemen laut MEDLINE: Gene Editing, Retinal Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Abnormal angiogenesis is associated with myriad human diseases, including proliferative diabetic retinopathy (PDR). Signaling transduction through phosphoinositide 3-kinases (PI3Ks) plays a critical role in angiogenesis. Herein, we showed that p110δ, the catalytic subunit of PI3Kδ, was highly expressed in pathological retinal vascular endothelial cells (ECs) in a mouse model of oxygen-induced retinopathy (OIR) and in fibrovascular membranes from patients with PDR. To explore novel intervention with PI3Kδ expression, we developed a recombinant dual adeno-associated viral (rAAV) system for delivering CRISPR/Cas9 in which Streptococcus pyogenes (Sp) Cas9 expression was driven by an endothelial specific promoter of the intercellular adhesion molecule 2 (pICAM2) to edit genomic Pik3cd, the gene encoding p110δ. We then demonstrated that infection of cultured mouse vascular ECs with the dual rAAV1s of rAAV1-pICAM2-SpCas9 and rAAV1-SpGuide targeting genomic Pik3cd resulted in 80% DNA insertion/deletion in the locus of genomic Pik3cd and 70% depletion of p110δ expression. Furthermore, we showed that in the mouse model of OIR editing retinal Pik3cd with the dual rAAV1s resulted in not only a significant decrease in p110δ expression, and Akt activation, but also a dramatic reduction in pathological retinal angiogenesis. These findings reveal that Pik3cd editing is a novel approach to treating abnormal retinal angiogenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Hunan Key Laboratory of Ophthalmology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
- Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Ophthalmology, The Third Affiliated Hospital of Xinxiang Medical University, Eye Hospital of Xinxiang Medical University, Xinxiang, China.
- Shenzhen Eye Hospital, Jinan University, Shenzhen Eye Institute, Shenzhen, China.
- Huan Key Laboratory of Molecular Precision Medicine, Xiangya Hospital and Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Central South University, Changsha, China.
ORCID-Profile: Wenyi Wu, Hetian Lei
Zitieren
APA
Wu, W., Ma, G., Qi, H., Dong, L., Chen, F., Wang, Y., Mao, X., Guo, X., Cui, J., Matsubara, J. A., Vanhaesebroeck, B., Yan, X., Zhao, G., Zhang, S., & Lei, H. (2023). Genome Editing of Pik3cd Impedes Abnormal Retinal Angiogenesis. Human Gene Therapy. https://doi.org/10.1089/hum.2022.079
Vancouver
Wu W, Ma G, Qi H, Dong L, Chen F, Wang Y, et al. Genome Editing of Pik3cd Impedes Abnormal Retinal Angiogenesis. Human Gene Therapy. 2023. doi:10.1089/hum.2022.079
BibTeX
@article{Wu2023,
author = {Wu, Wenyi and Ma, Gaoen and Qi, Hui and Dong, Lijun and Chen, Fang and Wang, Yun and Mao, Xingxing and Guo, Xiaoqing and Cui, Jing and Matsubara, Joanne Aiko and Vanhaesebroeck, Bart and Yan, Xiaohe and Zhao, Guoming and Zhang, Shaochong and Lei, Hetian},
title = {Genome Editing of Pik3cd Impedes Abnormal Retinal Angiogenesis},
journal = {Human Gene Therapy},
year = {2023},
doi = {10.1089/hum.2022.079}
}
EUVIMED